Small Molecule Related Topics 
Drug Discovery World
FEBRUARY 2, 2024
The company is building a pipeline of small molecule drugs targeting novel proteins across the DNA mismatch repair (MMR) pathway to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. NeoPhore has announced a further extension of £9.6 million (approximately $12.2 million).
Drug Discovery World
DECEMBER 21, 2023
Biologics need to justify cost Companies in this sector will need to contend with the emergence of novel small molecules, particularly Janus kinase (JAK) and sphingosine 1 phosphate receptor modulators (S1PR). The post Biologics for bowel disease face threat from cheaper small molecules appeared first on Drug Discovery World (DDW).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
SEPTEMBER 28, 2023
Biomia says it plans to use the investment to accelerate its development of plant-inspired natural and new-to-nature halogenated small molecule drug candidates and further build its biosynthetic manufacturing platform.
Drug Hunter
APRIL 20, 2023
Through a series of structure-based design, ADME and solubility optimization, LP0200 was shown to exhibit high potency and safety comparable to approved IL-17A and IL-17RA targeting mAbs (more in our report of first disclosures from the EFMC-ISMC and this article on small molecule immunomodulators ). LP0200 has completed a Ph.
Covalent Modifiers
MARCH 22, 2024
Here, we report the chemical proteomic discovery of electrophilic small molecules that stereoselectively and site-specifically bind the pioneer TF, FOXA1, at a cysteine (C258) within the forkhead DNA-binding domain. Chemical probes are lacking for pioneer TFs, which has hindered their mechanistic investigation in cells.
Chemical Biology and Drug Design
JANUARY 29, 2024
Knowledge of the molecular interactions acquired from such structures would greatly aid the discovery of small molecule inhibitors of sPLA 2 s for the treatment of snakebite envenoming. In addition, the complex of the sPLA 2 inhibitor, varespladib, with a Lys49-PLA 2 -like snake venom toxin is also discussed.
Covalent Modifiers
FEBRUARY 15, 2024
Herein, we use afatinib as a lead to undertake a structure-based drug design approach, aided by mass-spectrometry and x-ray crystallography, to develop DHC-156, a small molecule that more selectively binds brachyury and downmodulates it as potently as afatinib.
Expert insights. Personalized for you.
130 
Let's personalize your content